Regenerex Pharma Financials
This page shows Regenerex Pharma (RGPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Regenerex Pharma passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Regenerex Pharma generates $0.64 in operating cash flow (-$1.6M OCF vs -$2.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Regenerex Pharma earns $-5.7 in operating income for every $1 of interest expense (-$1.8M vs $320K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Regenerex Pharma's EBITDA was -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 47.3% from the prior year.
Regenerex Pharma reported -$2.5M in net income in fiscal year 2025. This represents an increase of 28.7% from the prior year.
Regenerex Pharma held $653K in cash against $0 in long-term debt as of fiscal year 2025.
Regenerex Pharma had 281M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.
Regenerex Pharma invested $662K in research and development in fiscal year 2025. This represents a decrease of 72.4% from the prior year.
RGPX Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $136K | N/A | N/A | $17K | N/A | N/A | N/A | N/A |
| SG&A Expenses | $650K+2.6% | $634K | N/A | $294K+13.8% | $258K+1.6% | $254K | N/A | $239K |
| Operating Income | -$787K-24.1% | -$634K | N/A | -$312K-20.6% | -$258K-1.6% | -$254K | N/A | -$239K |
| Interest Expense | $23K-3.7% | $24K | N/A | $27K-89.8% | $266K+1091.8% | $22K | N/A | $20K |
| Income Tax | -$50+55.8% | -$113 | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$814K-22.7% | -$664K | N/A | -$315K+40.6% | -$530K-94.3% | -$273K | N/A | -$264K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RGPX Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $618K-19.1% | $763K-39.6% | $1.3M+95.3% | $647K+2.2% | $633K-13.2% | $729K-4.9% | $767K-10.0% | $852K |
| Current Assets | $48K-74.9% | $193K-70.5% | $653K+66031.1% | $988-46.2% | $2K-22.1% | $2K-19.1% | $3K-68.6% | $9K |
| Cash & Equivalents | $12K-93.2% | $172K-73.6% | $653K+193102.7% | $338+15.0% | $294 | $0-100.0% | $372-95.3% | $8K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.3M+0.1% | $5.3M-2.0% | $5.4M-4.9% | $5.7M+5.8% | $5.4M+6.9% | $5.0M+4.4% | $4.8M+2.1% | $4.7M |
| Current Liabilities | $4.9M+1.5% | $4.9M-1.4% | $4.9M-4.6% | $5.2M+6.4% | $4.9M+9.9% | $4.4M+14.8% | $3.8M+8.0% | $3.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | $184K | N/A |
| Total Equity | -$4.7M-3.3% | -$4.5M-9.4% | -$4.2M+17.8% | -$5.1M-6.2% | -$4.8M-10.3% | -$4.3M-6.2% | -$4.1M-4.8% | -$3.9M |
| Retained Earnings | -$9.6M-9.2% | -$8.8M-8.1% | -$8.1M-20.9% | -$6.7M-4.9% | -$6.4M-9.0% | -$5.9M-4.9% | -$5.6M-5.5% | -$5.3M |
RGPX Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$519K-8.7% | -$478K+62.8% | -$1.3M-709.4% | -$159K-25.4% | -$127K-128.8% | -$55K+14.1% | -$64K+35.5% | -$100K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Financing Cash Flow | $398K+15088.8% | -$3K-100.1% | $1.9M+1121.1% | $159K+25.1% | $127K+130.9% | $55K-3.5% | $57K-43.9% | $102K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
RGPX Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -131.8%-44.8pp | -86.9% | N/A | -48.6%+35.0pp | -83.7%-46.3pp | -37.4% | N/A | -31.0% |
| Current Ratio | 0.01-0.0 | 0.04-0.1 | 0.13+0.1 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00 |
| Debt-to-Equity | -1.13+0.0 | -1.17+0.1 | -1.30-0.2 | -1.130.0 | -1.13+0.0 | -1.17-1.1 | -0.05+1.2 | -1.22 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$4.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.13), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
Is Regenerex Pharma profitable?
No, Regenerex Pharma (RGPX) reported a net income of -$2.5M in fiscal year 2025.
What is Regenerex Pharma's EBITDA?
Regenerex Pharma (RGPX) had EBITDA of -$1.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Regenerex Pharma's operating cash flow?
Regenerex Pharma (RGPX) generated -$1.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Regenerex Pharma's total assets?
Regenerex Pharma (RGPX) had $1.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Regenerex Pharma spend on research and development?
Regenerex Pharma (RGPX) invested $662K in research and development during fiscal year 2025.
How many shares does Regenerex Pharma have outstanding?
Regenerex Pharma (RGPX) had 281M shares outstanding as of fiscal year 2025.
What is Regenerex Pharma's current ratio?
Regenerex Pharma (RGPX) had a current ratio of 0.13 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Regenerex Pharma's debt-to-equity ratio?
Regenerex Pharma (RGPX) had a debt-to-equity ratio of -1.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regenerex Pharma's return on assets (ROA)?
Regenerex Pharma (RGPX) had a return on assets of -200.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regenerex Pharma's cash runway?
Based on fiscal year 2025 data, Regenerex Pharma (RGPX) had $653K in cash against an annual operating cash burn of $1.6M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Regenerex Pharma's debt-to-equity ratio negative or unusual?
Regenerex Pharma (RGPX) has negative shareholder equity of -$4.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Regenerex Pharma's Piotroski F-Score?
Regenerex Pharma (RGPX) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regenerex Pharma's earnings high quality?
Regenerex Pharma (RGPX) has an earnings quality ratio of 0.64x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regenerex Pharma cover its interest payments?
Regenerex Pharma (RGPX) has an interest coverage ratio of -5.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.